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The most common cutaneous T-cell lymphomas (CTCLs) – mycosis fungoides (MF) and Se ´zary Syndrome – are characterised by the
presence of clonally expanded, skin-homing helper-memory T cells exhibiting abnormal apoptotic control mechanisms. Epigenetic
modulation of genes that induce apoptosis and differentiation of malignant T cells may therefore represent an attractive new strategy
for targeted therapy for T-cell lymphomas. In vitro studies show that vorinostat (suberoylanilide hydroxamic acid or SAHA), an oral
inhibitor of class I and II histone deacetylases, induces selective apoptosis of malignant CTCL cell lines and peripheral blood
lymphocytes from CTCL patients at clinically achievable doses. In a Phase IIa clinical trial, vorinostat therapy achieved a meaningful
partial response (450% reduction in disease burden) in eight out of 33 (24%) patients with heavily pretreated, advanced refractory
CTCL. The most common major toxicities of oral vorinostat therapy were fatigue and gastrointestinal symptoms (diarrhoea, altered
taste, nausea, and dehydration from not eating). Thrombocytopenia was dose limiting in patients receiving oral vorinostat at the
higher dose induction levels of 300mg twice daily for 14 days. These studies suggest that vorinostat represents a promising new
agent in the treatment of CTCL patients. Additional studies are underway to define the exact mechanism (s) of by which vorinostat
induces selective apoptosis in CTCL cells and to further evaluate the antitumour efficacy of vorinostat in a Phase IIb study in CTCL
patients.
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Cutaneous T-cell lymphomas (CTCLs) represent a heterogeneous
group of extra-nodal non-Hodgkin lymphomas. Mycosis fungoides
(MF) and its leukaemic variant, Se ´zary syndrome (SS), are the
most frequently encountered types of CTCL. They are charac-
terised by progressive clonal expansion of CD4þCD45ROþ
CLAþCCRþ helper/memory T cells that do not express the
typical T-cell surface markers (CD7 and/or CD26) (Kim et al,
2005). In contrast to their normal counterparts, these malignant T
cells exhibit abnormal apoptotic control mechanisms resulting in
prolonged lifespans and are typically very resistant to treatment
regimens, including chemotherapeutic agents (Meech et al, 2001).
Epigenetic modulation of genes that induce apoptosis and
differentiation of malignant T cells may therefore represent an
attractive new strategy for targeted therapy of CTCL.
Recent studies in our laboratory (Zhang et al, 2005) indicate that
vorinostat (suberoylanilide hydroxamic acid or SAHA), an oral
inhibitor of class I and II histone deacetylases (HDACs), induces
apoptosis of malignant CTCL cell lines and peripheral blood
lymphocytes from SS patients cells at clinically achievable doses.
These data suggest that alterations in HDAC activity may be
involved in the pathogenesis of T-cell lymphomas and that
vorinostat may be clinically effective in treating T-cell lymphomas.
This article provides a brief overview of the pathophysiology of
CTCL, summarises the spectrum of currently available treatment
options, and finally reviews data from preclinical studies as well as
ongoing or recently completed clinical trials evaluating the
antitumour efficacy of vorinostat in patients with refractory or
relapsed CTCL patients unresponsive to conventional therapy.
PATHOPHYSIOLOGY AND PROGNOSIS
Mycosis fungoides represents the most common and indolent form
of CTCL and was originally described more than 200 years ago
(Girardi et al, 2004). A key characteristic of MF is the presence of
malignant skin-homing T cells possessing distinct markers
(CD4þCD45ROþCLAþCCRþ) but lacking the usual T-cell
surface markers CD7 and/or CD26. Although many clinical
variants of this lymphoma are described, the most common
clinical presentation is of pink to red patches or plaques appearing
in sun-shielded areas. Lesions are often accompanied by variable
degrees of pruritus (Girardi et al, 2004; Kazakov et al, 2004).
Mycosis fungoides may progress over many years from the early
patch/plaque T1–T2 stages to more advanced stages involving
tumours (which frequently ulcerate), erythroderma, blood or
organ involvement, and ultimately death from infection (Girardi
et al, 2004). A leukaemic variant characterised by generalised
erythroderma and the presence of abnormal circulating malignant
T cells is referred to as SS. Patients with SS not only exhibit
erythroderma but often have intractable itching and frequently are
colonised by Staphylococcus aureus (Jackow et al, 1997). Circula-
ting malignant lymphocytes have convoluted nuclei (referred to as
Se ´zary cells, after the French dermatologist who discovered them) *Correspondence: Dr M Duvic; E-mail: mduvic@mdanderson.org
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et al, 2001; Washington et al, 2002).
The initial trigger leading to the development of skin-homing
CD4þ cells in MF/SS is unclear, although environmental and
infectious agents have been hypothesised. MF has an association
with class II HLA DR5 and DQB*03 alleles, suggesting that it may
be an autoimmune disease triggered by antigen presentation
(Jackow et al, 1996). Also supporting this hypothesis is the
pathologic finding of atypical, malignant epidermotropic
CD4þlymphocytes clustering around epidermal Langerhans
forming the characteristic Pautrier microabscesses (Girardi et al,
2004; Kim et al, 2005). Immature dendritic cells (Langerhans cells)
in the epidermis may play an intimate role in the early
pathogenesis of MF/SS by activating T cells through direct contact
and providing the impetus for their clonal expansion (Berger et al,
2002). Progression of MF/SS is accompanied by clonal dominance
of the malignant cells, (Vega et al, 2002) leading to the elaboration
of Th2 cytokines, (Rook et al, 1997) impairment of the host’s
immune response, and further tumour cell growth (Girardi et al,
2004; Kim et al, 2005).
The survival of MF/SS patients varies markedly with the stage of
disease at presentation, and although difficult to study, may in part
be dependent on whether immunosuppressive therapy is adminis-
tered (Table 1) (Kim and Hoppe, 1999; Kim et al, 1999; Zackheim
et al, 1999). Patients in the early stages of MF are treated with
topical agents and show a median survival not unlike that of
matched control populations. Patients with advanced stages IVA-B
defined by pathologically involved lymph nodes, blood, or visceral
involvement have a poor prognosis, with a median survival of only
2.5 years in some studies (Kim and Hoppe, 1999). The appearance
of large cell transformation within 2 years of diagnosis is also
associated with a poor prognosis (Diamandidou et al, 1998).
CURRENT TREATMENT OPTIONS
The primary goal of any therapy is to induce a long-term complete
remission or cure. However, a less ambitious goal of decreasing the
tumour burden, improving symptoms, and preserving quality of
life, without further impacting the patient’s already compromised
immune system, is a more realistic situation. There are a limited
number of therapeutic modalities, including skin-directed thera-
pies, biologic-response modifiers, systemic agents, and experi-
mental therapies, available to treat patients with MF/SS (Table 2).
However, only extracorporeal photopheresis, denileukin diftitox,
and bexarotene have FDA approval for this specific indication. In
general, MF/SS is managed according to the stage of the disease
(Table 3). Treatment decisions may be influenced by weighing the
expected benefits against drug toxicities, patient tolerance and
convenience, cost, and compliance with therapy.
Patients with early stages of MF have disease localised to the
skin, where it can often be put into remission with skin-directed
therapies. The usual progression of treatment begins with topical
steroids or retinoid, followed by either topical chemotherapy with
mustargen (mechlorethamine HCl) or with one form of photo-
therapy. Combinations of topical and phototherapy may hasten the
time to response. Total skin electron beam irradiation is generally
reserved for patients with generalised skin involvement, thick
plaques, or tumours who have failed topical therapies. Aggressive
chemotherapy cannot be justified for early MF because it does not
prolong overall survival in comparison to conservative sequential
therapy (Kaye et al, 1989).
In patients who fail to respond to skin-directed therapy or have
more extensive lesions, the addition of biological response
modifiers is the accepted therapeutic choice. As discussed in a
previous detailed reviews of the literature, (Kempf et al, 2003;
Zhang and Duvic, 2003) oral retinoids, either alone, or in
combination with other skin-directed or biological response
modifiers, represent a good low-risk treatment modality to control
early MF. Retinoic acid receptor selective retinoids (isotretinoin
and etretinate) are similar in efficacy with response rates of about
50% reported for each agent. Bexarotene oral capsules as
monotherapy were able to induce responses in 54% of early
(Duvic et al, 2001b) and 45% risk reduction of advanced,
refractory CTCL at the optimised dose of 300mgm
 2 in two
clinical Phase II trials (Duvic et al, 2001a, b). Combined treatment
modalities, including the retinoid isotretinoin, followed by TSEB
(for stage I–II disease) or preceded by chemotherapy (for stage II
and IV disease) (Duvic et al, 2003a) bexarotene plus PUVA, or
photopheresis plus alpha interferon (IFN) and low-dose bexa-
rotene, (Rook et al, 1999a) have been reported to give overall
response rates of 82% in MF patients and 69% in SS patients
(Kempf et al, 2003). Combinations of bexarotene with other
modalities were most effective when one or two lipid-lowering
agents and synthroid were simultaneously administered, giving
response rates of over 70% (Talpur et al, 2002). Retinoids can be
given orally, are active in 50% of the patients, and are a generally
well tolerated first-line systemic therapy of CTCL; however,
patients may fail to reach complete remission or may relapse
while on treatment, requiring other approaches and therapies.
Another agent to show promise in treating CTCL is the tumour-
targeted fusion protein, denileukin diftitox (Olsen et al, 2001). In
patients with stage Ib to IVa CTCL who had received 43 prior
therapies, denileukin diftitox therapy (9 or 18mgkg
 1day
 1 for 5
days every 3 weeks for up to eight cycles) produced an overall
response rate of 30% (20% partial response (PR), 10% complete
response (CR)) and mediation duration of response of 6.9 months
(range, 2.7 to 446.1 months). Pre-administration of low-dose
corticosteroids with denileukin diftitox infusions blocked the
commonly encountered infusion reactions and improved the
response rate to 60% (Foss et al, 2001). Denileukin diftitox can
produce a vascular leak syndrome (hypotension, hypoalbumine-
mia, and oedema), which can be partially prevented by saline
infusions post-treatment. It can also induce a hypersensitivity
reaction or transaminase elevations in some patients.
Patients with more advanced MF/SS or those who relapse and
become resistant to initial treatments require a more aggressive
therapeutic approach, which may involve biologic response
modifiers, combination therapies, bone marrow transplantation,
or chemotherapy. In addition to retinoids, both alpha and gamma
Table 1 Prognosis of CTCL patients according to tumour stage at presentation
Stage Description Survival
1A T1, patches and/or plaques involving o10% BSA with no palpable adenopathy Similar to age-matched controls (Kim et al, 1999; Zackheim et al, 1999)
1B T2, patches and/or plaque involving at X10% BSA with no palpable adenopathy X67% at 10 years (Kim et al, 1999; Zackheim et al, 1999)
IIA T1/T2, patches and/or generalised plaque, clinically abnormal lymph nodes
IIB T3, cutaneous tumours 5 years (Kim and Hoppe, 1999)
III T4, generalised erythroderma
IVA-B Pathologically involved lymph nodes or visceral involvement 2.5 years (Kim and Hoppe, 1999)
BSA¼body surface area.
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latory activity in CTCL. Alpha IFN combined with photopheresis
and a retinoid are first line treatments for patients with SS
(Gottlieb et al, 1996; Duvic et al, 2003b). Another biological
response modifier, interleukin 12, has shown activity in three
separate clinical trials and increases CD8þ T-cell infiltrates in
CTCL lesions (Rook et al, 1999b).
Although combined chemotherapeutic regimens (e.g., CHOP
(cyclophosphamide, vincristine, doxorubicin, prednisone), CMED
(cyclophosphamide, methotrexate, etoposide, and dexametha-
sone), and ESHAP (etoposide, methyl prednisolone, high-dose
cytarabine, and cisplatin)) have been utilised in treating CTCL and
have response rates of about 60%, the duration of responses seen
may be disappointingly brief. Combined chemotherapy often
requires the placement of central lines, which in turn increase the
risk of potentially fatal opportunistic infections in the setting of a
compromised host immune system.
Nucleoside agents have recently been studied for treatment of
advanced patients with CTCL. Several phase II studies concluded
that gemcitabine has high response rates of 70% in patients with
Table 2 Overview of current therapeutic options for MF/SS
Skin-directed therapy
K Topical corticosteroids (Farber et al, 1968; Zackheim et al, 1998)
K Topical chemotherapy (e.g., nitrogen mustard, (Vonderheid et al, 1989) carmustine (Zackheim et al, 1990))
K Topical retinoids (bexarotene, (Duvic et al, 2001a; Breneman et al, 2002) tazarotene (Apisarnthanarax et al, 2004))
K Topical imiquimod (Didona et al, 2004)
K Phototherapy (UVB, (Ramsay et al, 1992) NbUVB, (Gathers et al, 2002) PUVA (Herrmann et al, 1995))
K Electron beam therapy (Jones et al, 1995)
Biological therapy
K RXR retinoid (bexarotene) (Breneman et al, 2002; Duvic et al, 2001b)
K RAR retinoid (isotretinoin) (Neely et al, 1987)
K Interferons (Olsen, 2003)
K Granulocyte–macrophage colony-stimulating factor (Bouwhuis et al, 2002)
K Extracorporeal photopheresis (Duvic et al, 2003b)
K Fusion protein/toxin (denileukin diftitox) (Olsen et al, 2001)
Other systemic therapies
K Cytotoxic chemotherapy (methotrexate, (Zackheim et al, 2003) doxil,(Di Lorenzo et al, 2005) gemcitabine, (Sallah et al, 2001) etoposide, (Onozuka et al, 2004)
pentostatin (Dearden et al, 2000))
K Bone marrow/stem cell transplantation (Soligo et al, 2003; Guitart et al, 2002)
Experimental therapies
K HDAC inhibitors (vorinostat, (Duvic et al, 2005) depsipeptide (Piekarz et al, 2001))
K Transimmunisation extracorporeal photopheresis (Girardi et al, 2002)
K Targeted monoclonal antibodies (CD52, (Lundin et al, 1998; Lundin et al, 2003) CCR4(Niwa et al, 2004)}, CD4 (McFarlane et al, 2005))
K Cytokines (IL-12, IL-2 (Rook et al, 2003))
K TLR agonists (CpG oligodeoxynucleotides) (Wysocka et al, 2004)
K Tumour vaccines (Seo et al, 2003)
UVB¼ultraviolet B light, NbUVB¼narrow-band ultraviolet B light, PUVA¼psoralen plus ultraviolet A light, RXR¼retinoid X receptor, RAR¼retinoic acid receptor,
TLR¼toll-like receptor 9 ; IL¼interleukin. Information extracted from Kim EJ et al, J Clin Invest 2005; 115:798–812.
Table 3 Overview of initial and subsequent treatment options by stage for patients with MF/SS
TNMB classification and staging
IA IB-IIA IIB IIIA,B IVA,B
Initial therapy
Skin directed-therapies – topical
chemotherapy
PUVA
UVB
Local EBT
Topical chemotherapy
Phototherapy
TSEBT
PUVA
Discrete tumours:
– Local EBT+topical chemotherapy
or PUVA
Generalised tumours:
– TSEBT+topical chemotherapy
– PUVA+INF-a
– PUVA+retinoids
– Denileukin diftitox
ECPP
PUVA
Retinoids
INF-a
Methotrexate
Topical therapy+
– Palliative systemic chemotherapy
– Combined systemic therapies
(e.g., INF-a, retinoids, ECPP)
– Local radiation for
extracutaneous disease
Subsequent therapy
IFN-a
Retinoids combined therapies
– TSEBT/PUVA+topical
chemotherapy
– PUVA+INF-a
– PUVA+retinoids
– TSEBT+INF-a
Other combined therapies
– TSEB+ECPP
– Retinoids+INF-a
– TSEBT+chemotherapy
Combined
therapies:
– ECPP+INF-a
– PUVA+INF-a
– PUVA+retinoids
– Retinoids+INF-a
Bone marrow/stem cell transplant
Salvge therapy
Newer/investigational therapies
PUVA¼oral psoralen-UV-A, EBT¼electron beam therapy, TSEBT¼total skin electron beam therapy, INF-a¼interferon-a,E C P P¼extracorporeal photopheresis Information
extracted from Kim EJ et al (Kim et al, 2005) and Kim YH and Hoppe RT (Kim and Hoppe, 1999).
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especially active against tumours (Duvic et al, 2006b) and is well
tolerated, with minimal toxicity. Pentostatin has been studied as
well and shows 60% response rates in patients with SS but is less
active against tumours and nodal disease where the duration of
response is only a few months (Kurzrock et al, 1999). Chemo-
therapy should be used for palliation in patients with nodal or
visceral involvement or large cell transformation.
Bone marrow transplantation (autologous and allogeneic) has
been employed to treat advanced CTCL but the overall clinical
experience to date is limited to less than 20 patients. Autologous
transplants have not cured the disease whereas non-ablative
allogenic transplants show more promise in putting patients into
complete remissions. Nevertheless, allogeneic transplantion was
reported to produce remissions of 4.5 years, 15 months, and 9
months in three patients (Guitart et al, 2002). Further, the results
of a retrospective study evaluating outcome in advanced CTCL
patients population suggests that allogeneic haematopoietic stem-
cell transplantation can induce durable clinical, molecular, and
cytogenetic remissions in patients with advanced CTCL refractory
to standard therapies (Molina et al, 2005).
It is clear from these studies that patients with refractory or
transformed MF and with SS have a generally poor prognosis and
therapy is typically palliative. There is an urgent need for new
therapies, especially ones capable of reversing the defective
apoptosis that is a characteristic of all CTCL cells. HDAC inhibitors
such as vorinostat, may modulate the expression of genes
controlling growth and differentiation of T-cell lymphomas and
may represent an attractive new strategy for targeted therapy of
CTCL.
EVALUATION OF VORINOSTAT IN CTCL
Preclinical studies
Vorinostat demonstrates potent anti-tumour effects against three
well-established CTCL cell lines (MJ [G11], Hut78, and HH) as well
as in freshly isolated peripheral blood lymphocytes from 11
patients with a high percentage of circulating malignant T cells
(Zhang et al, 2005). As shown in Figure 1, vorinostat inhibited cell
growth of MJ, Hut78, and HH cell lines in a dose-dependent and
time-dependent manner. For example, increasing the dose of
vorinostat from 1 to 5mM increased growth inhibition of HH cells
from 2 to 34% at 24h and from 21 to 70% at 48h. Analysis of the
distribution of cells in various phases of the cell cycle using flow
cytometry revealed that growth inhibition induced by vorinostat
was associated with an increase in the percentage of cells in sub-G1
population and a loss of cells in the G1, S, and G2/M phases,
suggesting vorinostat induces apoptosis (Zhang et al, 2005).
The proapoptotic effect of vorinostat was confirmed in vitro by
flow cytometric analysis of annexin V protein binding to the cell
surface of CTCL cell lines and freshly isolated peripheral blood
lymphocytes from CTCL patients (Zhang et al, 2005). Annexin V
binding is a novel technique to detect apoptosis and works by
binding to phosphatidylserine residues at the outer plasma
membrane. These residues become exposed as a result of loss of
phospholipid asymmetry of the plasma membrane, an early event
in apoptosis. Vorinostat increased the proportion of cells binding
annexin V in all three CTCL cell lines (Figure 2) (Zhang et al,
2005). Importantly, vorinostat was associated with selective
apoptosis, as evidenced by the ability of vorinostat to increase
annexin V binding to freshly isolated peripheral blood lympho-
cytes obtained from SS/MF patients but to lymphocytes isolated
from healthy donors.
Mechanism of selective apoptotic action in CTCL cells
Selective apoptosis produced by vorinostat may potentially involve
a variety of mechanisms, including an increase in p21
WAF1,a n
alteration in bax/bcl-2 ratio, a decrease in Stat6 and phosphor-
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Figure 1 Vorinostat inhibited cell growth in three CTCL cell lines
incubated in vitro for 24 or 48h. Cells were aliquoted into 96-well plates
and cell viability measured spectrophometrically at 490nm after 4h
following addition of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt. Reproduced with
permission from Zhang C et al, J Invest Dermatol 2005 (Zhang et al, 2005).
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Figure 2 Effect of increasing doses of vorinostat on apoptosis assessed by annexin V binding in three CTCL cell lines after 24 or 48h of incubation.
Reproduced with permission from Zhang C et al, J Invest Dermatol 2005 (Zhang et al, 2005).
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At this juncture, it seems unlikely that differences in the ability of
vorinostat to inhibit HDAC activity or regulate the expression of
key genes are the primary hypothetical mechanisms for differential
sensitivity of tumour and normal cells to this agent. This assertion
is based on the observations that the addition of vorinostat results
in accumulation of acetylated histones in both normal fibroblasts
from human lung and breast as well as transformed cells (WI-38,
VA 13, and ARP-1), CTCL cell lines (MJ, Hut78, and HH),
and peripheral blood lymphocytes from two patients with SS
(Ungerstedt et al, 2005; Zhang et al, 2005). Nevertheless, the results
presented by Ungerstedt et al (2005) do indicate that vorinostat
may cause an accumulation of reactive oxygen species (ROS) and
caspase activation in transformed but not normal cells as well as an
increase in the level of Trx, a major reducing protein for many
targets, in normal cells but not in transformed cells (Zhang et al,
2005).
Our in vitro studies (Zhang et al, 2005) of CTCL cell lines
revealed that vorinostat at concentrations associated with
apoptosis resulted in induction of expression of p21
WAF1,
a protein that has been shown to be responsible for cell cycle
arrest and apoptosis induced by HDAC inhibitors (Mei et al,
2004; Somech et al, 2004). Although upregulation of p21
WAF1
occurred in response to vorinostat, immunoblot analysis showed
that this effect was independent of the tumour suppressor p53.
In addition, vorinostat was found to impact the nuclear to
cytoplasmic expression of p-Stat stat 3 proteins in CTCL cell lines
(Duvic et al, 2006a). Stat proteins represent a family
of transcription factors that, once activated, are believed to
contribute to oncogenesis by stimulating cell proliferation
and preventing apoptosis (Sommer et al, 2004; Turkson, 2004;
Mitchell and John, 2005). Vorinostat at concentrations capable of
producing apoptosis, decreased the expression of Stat6 and
phosphor-Stat6 (but not Stat3 and phosphor-Stat3) in CTCL cell
lines and peripheral blood lymphocytes from SS patients. Clearly,
further research is needed to explore all of these mechanisms in
greater detail.
Phase I study
A recently completed phase I study of patients with advanced
cancer described the effect of oral vorinostat in a patient with
CTCL who had failed to respond to a total of five previous systemic
therapies. Oral vorinostat administered at a dose of 200mg twice
daily for a total of 4 months resulted in a stabilisation of the
disease. Although a second patient with peripheral T-cell
lymphoma was enrolled, the report did not appear to describe
the outcome of this patient. This finding is consistent with a recent
phase I trial of another HDAC inhibitor (FR901228), which showed
a PR in three patients with CTCL and one patient with peripheral
T-cell lymphoma (Piekarz et al, 2001).
Phase II study
In light of the favourable preclinical studies and the response of
the CTCL patient to oral vorinostat in the phase I trial, a phase IIA
clinical trial (Duvic et al, 2005) was conducted at our centre to
determine the response rate, duration of response, pruritus relief,
and safety profile of oral vorinostat in 33 patients with refractory
or relapsed CTCL (stages IA-IVB) unresponsive to at least one
conventional therapy. There were four patients who were treated
twice in different dosing cohorts.
Patients were required to have adequate bone marrow, liver,
and renal function, and an ECOG performance status of less
than or equal to 2. Enrolled patients were treated with continuous
daily dosing of oral vorinostat 400mg, intermittent dosing of
oral vorinostat 300mg twice daily (for 3 days with 4
days rest), or oral vorinostat according to an induction/rest/
continuous regimen (300mg twice daily for 14 days, with 7 days
rest followed by 200mg twice daily). The primary efficacy end
point of the study was the complete & partial response rate (CR,
PR). However, the study also evaluated time to response, time to
progressive disease, response duration, pruritus relief and safety.
The response to therapy was categorised according to the World
Health Organization criteria (Miller et al, 1981) as a CR, PR, stable
disease, or progressive disease. The safety of vorinostat was
assessed by utilising the National Cancer Institute Common
Toxicity Criteria version 2.
Based on a preliminary analysis of intent-to-treat data,
presented at the 2005 annual meeting of the American Society of
Clinical Oncology (Duvic et al, 2005), a total of 10 out of 37
patients with heavily pretreated advanced refractory CTCL patients
achieved a meaningful PR (450% reduction in disease burden).
Considering unique patients for an intent-to-treat analysis, eight
out of 33 or 24% of the patients achieved a documented PR and
there were no CRs (Duvic et al, 2006a).
The most common major toxicities that were possibly or
probably related to oral vorinostat therapy were fatigue and
gastrointestinal symptoms, including diarrhoea, altered taste,
nausea, and dehydration from not eating/drinking. Thrombocyto-
penia was dose limiting in patients receiving oral vorinostat at the
higher induction doses of 300mg twice daily for 14 days. Overall,
oral vorinostat at a dose of 400mg daily provided the most
favourable risk–benefit profile and, thus, this dose has been
selected for a second Phase IIB trial currently ongoing at multiple
centres.
The adverse effects associated with vorinostat therapy can be
managed in several ways. Dehydration in elderly patients can be
prevented by weighing patients at each visit, checking haemo-
globin and creatinine levels and by using fruit juice, popsickles,
smoothies, or sherbert to relieve a dry mouth and improve taste
and appetite. In addition, nausea and vomiting can be controlled
with ondansetron hydrochloride and diarrhoea treated with
lomotil. The risk of haematologic side effects can also be
minimised by avoiding aspirin and by monitoring for a rapid fall
in platelet counts or a rapid change in international normalised
ratio in those patients receiving coumadin.
CONCLUSIONS
The HDAC inhibitor vorinostat increases apoptosis of CTCL cells
in vitro at concentrations that are clinically relevant. Oral
vorinostat has a rapid onset of action and exhibits significant
clinical activity against transformed tumours, erythroderma, and
nodes in heavily pretreated, refractory CTCL patients. Most
patients with CTCL also experience significant itching relief with
vorinostat therapy, and, hence, a marked improvement in their
quality of life. Overall, vorinostat appears to be generally well
tolerated, with fatigue and gastrointestinal symptoms being the
most common side effects at lower doses and thrombocytopenia at
higher doses. These side effects were dose related and reversible
upon cessation of therapy. Additional studies are underway to
define the exact mechanism (s) of by which vorinostat induces
selective apoptosis in CTCL cells and to further evaluate the
antitumour efficacy of vorinostat in a Phase IIb study in CTCL
patients.
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